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land. Furthermore, Ct. felis often
feeds on humans. 
Clinicians encountering patients
with fever or rash (or both) and a his-
tory of cat contact or flea bites should
consider a diagnosis of R. felis.
Laboratory confirmation of infection
is not easy, but in vitro culture of R.
felis, and hence material for a sero-
logic assay for the diagnosis of
human R. felis infections, has recent-
ly been described, and serology
appears to be an accurate indicator of
exposure (9). As with other spotted
fever group rickettsial infections,
molecular diagnostics may provide a
useful alternative approach to detect-
ing and identifying R. felis in infected
tissues. In culture, R. felis has been
shown to be resistant to erythromycin
(unlike other rickettsia), gentamicin,
amoxicillin, and trimethoprim-sul-
famethoxazole. Thus, infection with
this bacterium should be considered
in cases of antibiotic-insensitive fever
with a rash, especially in young, old,
and immunosuppressed persons. The
organism is sensitive to doxycycline,
rifampicin, thiamphenicol, and fluo-
roquinolones (10)
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Community
Transmission of
Extended-Spectrum
β-Lactamase 
To the Editor: The spread of mul-
tiresistant gram-negative bacteria in
the general population is a problem of
paramount importance, but the
responsible mechanisms are poorly
understood. Several studies have
focused on β-lactam resistance in
Enterobacteriaceae isolated from
stools in healthy people, but they did
not specifically investigate the
extended-spectrum β-lactamases
(ESBL). Furthermore, none of these
studies detected ESBL in the evaluat-
ed population (1,2). We performed
three survey studies to determine the
incidence of Enterobacteriaceae
strains producing ESBLs in the stools
of outpatients attending our hospital.
The first study was performed during
a 4-month period (February–May
2001), the second during a 3 month-
period (April–June 2002), and the
third during 1 month (October 2002). 
Stool samples were spread onto
plates of MacConkey agar containing
2 mg/L of cefotaxime. A colony of
each distinct morphotype was ana-
lyzed further. Species were identified
according to conventional methods
(3). The susceptibility to β-lactam
antibiotics was determined by the
disk-diffusion test, following recom-
mendations of the National
Committee for Clinical Laboratory
Standards (4,5). The interpretative
reading of the antibiogram was per-
formed according to standard guide-
lines (4–6). The MICs of cefotaxime
and ceftazidime, with and without
clavulanic acid, were later determined
by Etest (AB Biodisk, Solna,
Sweden). Strains producing ESBL
were defined as strains showing syn-
ergism between amoxicillin-clavulan-
ic acid and cefotaxime, ceftazidime,
cefepime, or aztreonam (4,5).
All strains suspected of carrying a
resistance pattern compatible with
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hyperproduction of the chromosomal
enzymes, as well as resistant strains
without synergy, were disregarded.
During the first period, 15 (2.1%) of
707 outpatients were carriers of
Escherichia coli (14 patients) or
Proteus mirabilis (1 patient) with
ESBL. This percentage increased dur-
ing the second period, when 17
(3.8%) of 454 outpatients were carri-
ers of E. coli with ESBL, and again in
the third period, when 12 (7.5%) of
160 were carriers of E. coli (11
patients) or Enterobacter cloacae (1
patient) with ESBL. Characterization
of the different ESBL isolated during
the three study periods is in process.
Although Klebsiella pneumoniae car-
rying ESBL has been detected in our
hospital (7), as well as in other hospi-
tals in Barcelona (8), no ESBL-pro-
ducing K. pneumoniae strains were
identified in this survey.
Although we did not disregard
either the patients’ previous treatment
with antibiotics or previous hospital-
ization, these patients came to the
hospital from the community carrying
strains that express ESBL. Moreover,
during these three periods we
observed a significant increase in the
frequency of ESBL carriers (from
2.1% to 7.5%; p<0.005). These data
suggest that the community could be a
reservoir for these enzymes, as occurs
with other microorganisms (9–11).
Many questions remain unanswered
regarding the diffusion mechanisms
of this resistance in the community.
Confirmation of community-based
transmission of ESBL would indicate
a need for heightened vigilance and
further studies to determine the reser-
voirs and vehicles for dissemination
of ESBL within the community.
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Polymyxin-
Resistant
Acinetobacter spp.
Isolates: What Is
Next?
To the Editor: In Brazilian hospi-
tals, Acinetobacter spp. has been an
important etiologic agent of nosoco-
mial infections, mainly pneumonia
(1–3). In general, ampicillin/sulbac-
tam and carbapenems remain the last
therapeutic options for treatment of
such infections (3,4). However, resist-
ance rates to carbapenems have
increased, reaching rates approxi-
mately 12% or higher in some
Brazilian hospitals (1,3,4). Thus,
more toxic agents such as polymyxins
have been used as alternative thera-
peutic drugs against multidrug-resist-
ant Acinetobacter infections (5,6).
The clinical use of polymyxins has
been based on antimicrobial suscepti-
bility results and previous clinical
experience. However, the National
Committee for Clinical Laboratory
Standards (NCCLS) documents do
not currently provide interpretative
criteria for the testing of polymyxins
(7). In addition, the disk diffusion
technique was reported to be an unre-
liable method for evaluating the sus-
ceptibility to polymyxins (8). Since
Acinetobacter clinical specimens
exhibiting high MICs for polymyxins
(MIC, 8–32 µg/mL) were recently
detected, we searched for the frequen-
cy of occurrence of Acinetobacter
spp. strains exhibiting reduced sus-
ceptibility to polymyxin B among 100
bloodstream isolates of Acinetobacter
spp. (8). The bacterial isolates were
consecutively collected between
September 1999 and December 2000
from a tertiary Brazilian hospital,
